Next-Generation Bispecific Nanobody Targeting NT5E and EGFR for Advanced Colorectal Cancer Therapy

VHH-P824 is a humanized bispecific nanobody designed to target both 5'-nucleotidase ecto (NT5E) and epidermal growth factor receptor (EGFR). Currently in biological testing, it harnesses the potential of dual-targeting approaches for the treatment of colorectal cancer. By simultaneously engaging NT5E and EGFR, VHH-P824 aims to disrupt critical pathways involved in tumor growth and immune evasion. Its humanized single-chain format and rational molecular design offer opportunities for enhanced tumor penetration and reduced immunogenicity, positioning VHH-P824 as a promising candidate in the evolving landscape of colorectal cancer therapeutics.

Licensing Opportunity

VHH-P824 is available for out-licensing and strategic partnership discussions. We welcome inquiries from industry partners interested in advancing this innovative bispecific nanobody program for colorectal cancer therapy.

Development Phase

Modality

VHH-P824 is a bispecific antibody fusion featuring a single-chain variable fragment (scFv) that targets human CD73 (NT5E) and a camelid-derived single-domain antibody (nanobody) directed at EGFR, linked to an engineered IgG2-silent Fc region to abolish effector functions. The modular architecture provides a compact molecular size, superior tissue penetration, and enhanced stability compared to conventional antibodies. Expressed in human embryonic kidney cells, this format is optimized for manufacturability and scalability. For colorectal cancer, the dual-targeting and nanobody-based design may translate into improved tumor access and inhibition of both key oncogenic signaling and the immunosuppressive microenvironment.

Target

NT5E and EGFR are essential molecular targets in colorectal cancer biology. NT5E acts as an ectoenzyme involved in nucleotide metabolism and immune suppression, typically overexpressed in tumor microenvironments. EGFR, a transmembrane receptor tyrosine kinase, plays a pivotal role in signal transduction pathways controlling cell proliferation, survival, and differentiation, and is frequently upregulated in colorectal cancer cells. Both NT5E and EGFR are enriched in malignant epithelial tissues and tumor-associated stroma. Targeting NT5E inhibits adenosine-mediated immune evasion, while antagonizing EGFR disrupts oncogenic signaling, making their dual inhibition an attractive therapeutic strategy. VHH-P824 leverages simultaneous NT5E and EGFR blockade, offering strong strategic value for colorectal cancer intervention by addressing multiple tumor escape mechanisms.

Mechanism of Action

VHH-P824 operates by binding and neutralizing both NT5E and EGFR on colorectal cancer cells and within the tumor microenvironment. By targeting NT5E, VHH-P824 inhibits the enzymatic conversion of AMP to adenosine, resulting in reduced immunosuppression and enhanced antitumor immune activity. Concurrently, engagement of EGFR disrupts receptor-mediated signal transduction central to tumor cell proliferation and survival. The bispecific format effectively combines immune checkpoint inhibition with modulation of oncogenic signaling, addressing key pathological mechanisms in colorectal cancer. This nanobody fusion platform is amenable to further development, including antibody-drug conjugates and multi-specific constructs, broadening future therapeutic applications.

Colorectal Cancer

Colorectal cancer is among the most prevalent malignancies worldwide, representing a significant cause of cancer morbidity and mortality. It frequently develops through a stepwise accumulation of genetic and epigenetic alterations affecting epithelial cells of the colon and rectum. Risk factors include age, lifestyle, and genetic susceptibility. The mainstays of treatment encompass surgical resection, chemotherapy, and biological therapies, including anti-angiogenic and receptor-targeted agents. However, despite advances, patients with advanced disease often experience poor outcomes due to resistance to conventional therapies and tumor heterogeneity. Persistent challenges include metastatic disease, immune evasion, and the lack of effective second-line options for refractory cases. The development of VHH-P824, with its novel dual-targeting of NT5E and EGFR, holds promise to overcome several of these barriers. Its ability to modulate both tumor cell-intrinsic pathways and the immunosuppressive microenvironment represents a differentiated strategy with the potential to significantly impact patient care in colorectal cancer.